tbuckley/cabot-search huggingface dataset:
DEVELOPMENT OF A NOVEL DEEP LEARNING MODEL FOR RIGHT VENTRICULAR QUANTIFICATION ON ECHOCARDIOGRAPHY: A MULTIMODALITY VALIDATION STUDY
Authors: Ashley Beecy, Alex Bratt, Lillian Brouwer, Javid Alakbarli, Ines Sherifi, Richard Devereux, Jonathan Weinsaft, Jiwon Kim
Journal: Journal of the American College of Cardiology (2019)
COMPARISON BETWEEN DRUG-ELUTING STENT IMPLANTATION AND DRUG-COATED BALLOON ANGIOPLASTY IN PATIENTS WITH LEFT MAIN BIFURCATION IN-STENT RESTENOSIS LESIONS
Authors: Hyung Joon Joo, Han Saem Jeong, Duck Hyun Jang, Hyungdon Kook, Jae Hyoung Park, Soon Jun Hong, Cheol Woong Yu, Do-Sun Lim
Journal: Journal of the American College of Cardiology (2019)
CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS OF PATIENTS AT HIGH POLYGENIC RISK FOR CORONARY ARTERY DISEASE
Authors: Krishna G. Aragam, Mark Chaffin, George Hindy, Andrew Cagan, Lu-Chen Weng, Steven Lubitz, Jordan Smoller, Elizabeth Karlson, Amit V. Khera, Sekar Kathiresan, Pradeep Natarajan
Journal: Journal of the American College of Cardiology (2019)
Abstract 56: Growth Hormone Releasing Hormone Improves Sarcomere Relaxation and Calcium Decline in Cardiomyocyte From a Mouse Model of Heart Failure With Preserved Ejection Fraction
Authors: Raul A Dulce, Rosemeire M Kanashiro-Takeuchi, Lauro M Takeuchi, Wayne Balkan, Renzhi Cai, Andrew V Schally, Joshua M Hare
Journal: Circulation Research (2016)

Heart failure with preserved ejection fraction (HFpEF) is characterized by impaired relaxation, ventricular stiffening and fibrosis. Growth hormone releasing hormone (GHRH) agonists reduce fibrosis in rat and swine models of ischemic myocardial injury. However, their effect on cardiomyocytes is not known. We hypothesized that activation of GHRH receptor signaling improves impaired cardiomyocyte relaxation in a mouse model of HFpEF. C57BL6N mice (n=4-5) were implanted with a mini-osmotic pump to deliver angiotensin-II (Ang-II: 0.8 mg/kg/day) for 4 weeks and received daily injections of GHRH-Agonist (GHRH-A [MR-409]: 100 μg/kg) or vehicle (DMSO+propylene-glycol). Cardiomyocytes were isolated and calcium and sarcomere shortening assessed. Ang-II-treated cardiomyocytes exhibited reduced sarcomere length, indicating an inability to completely relax, despite lower resting calcium. These cardiomyocytes also exhibited impaired ability to contract with no changes in calcium transient amplitude, deficient relaxation and delayed calcium decay. MR-409 treatment restored resting calcium and resting sarcomere length; improved sarcomere shortening and completely abrogated Ang-II-induced delay in calcium decline and relaxation (see figure 1). Our findings demonstrate that chronic administration of Ang-II mediates structural and functional changes consistent with HFpEF and suggest that activation of the GHRH receptor signaling pathways prevents HFpEF-associated cardiomyocyte performance alterations.
Effect of daily azithromycin therapy and adherence on readmission risk in COPD
Authors: Jamuna K. Krishnan, Helen Voelker, John E. Connett, Dennis E. Niewoehner, Richard K. Albert, Paul D. Scanlon, Gerard J. Criner, Mark T. Dransfield, MeiLan K. Han, Fernando J. Martinez
Journal: European Respiratory Journal (2019)

<b>Patients with COPD who were randomised to azithromycin did not experience prolonged time to hospital readmission. There was a trend toward decreased risk of readmission when adjusted for total exposure to azithromycin.</b>http://ow.ly/NAzI30nb651
Comparative Assessment of FLT3 Variant Allele Frequency By Capillary Electrophoresis and Next-Generation Sequencing in FLT3mut+ patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Who Received Gilteritinib Therapy
Authors: Catherine C. Smith, Alexander E. Perl, Jessica K. Altman, Andrew Carson, Jorge E. Cortes, Timothy T Stenzel, Jason Hill, Qiaoyang Lu, Erkut Bahceci, Mark J. Levis
Journal: Blood (2017)
OUTCOMES ASSOCIATED WITH DIFFERENT TREATMENT PATTERNS AMONG PATIENTS HOSPITALIZED WITH ACUTE HEART FAILURE AND REDUCED EJECTION FRACTION IN THE UNITED STATES
Authors: Lei Chen, Raluca Ionescu-Ittu, Rebecca Burne, Sherry Shi, Annie Guerin, Eric Wu, Maria Borentain, Paul Kessler, Mary DeSouza, Aylin Tugcu, G. Michael Felker
Journal: Journal of the American College of Cardiology (2019)
A Contagion Model for Within-Family Transmission of Drug Abuse
Authors: Kenneth S. Kendler, Henrik Ohlsson, Jan Sundquist, Kristina Sundquist
Journal: American Journal of Psychiatry (2019)

Objective: The purpose of this study was to determine whether, controlling for genetic effects, drug abuse was transmitted within families as predicted by a contagion model. Methods: The authors examined 65,006 parent-offspring, sibling, and cousin pairs ascertained from Swedish population registries in which the primary case subject had a drug abuse registration. The rate of drug abuse registration among at-risk secondary case subjects ages 19–23 was studied. Utilizing matched control pairs, a difference-in-difference approach was used to infer causal effects. Results: In offspring, risk for drug abuse registration in the 3 years after an index registration of a parent residing in the same household, neighborhood, or municipality increased 5.9%, 3.4%, and 1.8%, respectively. For siblings of sibling index case subjects, parallel results were 5.9%, 3.9%, and 1.2%. For cousins of cousin index case subjects, excess risk for those in the same neighborhood or municipality was 2.9% and 0.9%, respectively. In all sets of relatives, drug abuse transmission was strongest in male-male pairs and in pairs closest in age. In sibling pairs, stronger transmission was observed in older to younger siblings compared with younger to older siblings. Transmission was stronger within than across the two drug classes with sufficient data (opiates and cannabis). Conclusions: These results suggest that drug abuse can be transmitted within families by an environmentally mediated temporally defined model of contagion. The most important methodological limitation is that drug abuse registration is an inaccurate measure of the onset of drug abuse. Indeed, as predicted, drug abuse risk increased among potential secondary case subjects in the year before drug abuse registration of the index case subject.
Abstract 295: Proteomic Profiling of Changes at Active Polysomes That Occur as a Response to Ischemic Injury and Reperfusion of the Heart
Authors: Miroslava Stastna, Amandine Thomas, Vidya Venkatraman, Roberta A Gottlieb, Jennifer E Van Eyk
Journal: Circulation Research (2018)

Introduction: Heart ischemic injury and subsequent reperfusion activate dynamic changes in protein expression that, we hypothesize, are regulated by alternative mechanism at active polysomes. Since analysis of mRNA can correlate poorly with protein composition, we applied proteomic approach to characterize the changes related to ischemia and reperfusion in proteins that comprise the ribosomes, proteins associated with translation machinery and the newly synthesized proteins. Methods: Mouse heart tissue homogenates for conditions of sham, ischemia and ischemia/reperfusion (n=5) were subjected to separation in sucrose gradient and resulted fractions containing high-efficiency polysomes (heavy), low-efficiency polysomes (light) and non-translating fraction (NT) for each condition were subjected to proteomic analysis. Results: We identified more than 1300 proteins in total. We defined the core of active polysomes to be composed of 500 proteins which were always present in heavy fraction regardless of conditions. While 60S- and 80S ribosomal proteins were present in both heavy and light fractions, 66 proteins of mitochondrial ribosomal complex (28S and 39S) were captured exclusively in light fraction. Of interest were proteins that were increased or decreased in heavy fraction after ischemia and ischemia/reperfusion. In particular, mitochondrial elongation factor Tu (EFTU) was increased while nuclear transcriptional activator (PURA) was decreased after ischemia, and both returned to control levels upon reperfusion. Several 60S- and 40S ribosomal proteins remained unchanged after ischemia but their levels decreased after reperfusion (e.g. L37a, S11, S12 and S19). Transport proteins such as protein of transmembrane 9 superfamily (TM9S2) and monocarboxylate transporter 1 (MOT1) were decreased in ischemia and remained decreased after reperfusion. Conclusion: The proteins associated with polysomes and translation machinery of diverse activity were identified and their expression changes triggered by heart ischemic injury and reperfusion were characterized. To our knowledge, this is the first extensive proteomic characterization of polysome-related proteins revealing their dynamic profiles after ischemic stress in the heart.
MISCLASSIFICATION OF MYOCARDIAL INJURY AS TYPE 2 MYOCARDIAL INFARCTION AND IMPLICATIONS FOR 30-DAY OUTCOMES
Authors: Cian P. McCarthy, Sean Murphy, Joshua A. Cohen, Saad Rehman, Maeve Jones-O'Connor, David Olshan, Avinainder Singh, Muthiah Vaduganathan, James Januzzi, Jason Wasfy
Journal: Journal of the American College of Cardiology (2019)
Abstract P305: Daily Walking Time and Pneumonia Mortality Among Elderly With/Without Medical History of Myocardial Infarction or Stroke
Authors: Shigekazu Ukawa, Wenjing Zhao, Hiroshi Yatsuya, Kazumasa Yamagishi, Hiroyasu Iso, Akiko Tamakoshi
Journal: Circulation (2017)

Several studies report that daily walking reduces the risk of pneumonia. However, the elderly often experience underlying chronic diseases such as myocardial infarction (MI) or stroke which also increase the risk of pneumonia; thus, the association of walking with pneumonia may merely be a result of confounding of the underlying conditions. Therefore, we explored the links between daily walking and pneumonia mortality stratified by the presence of medical histories in 22,280 Japanese elderly (9,067 men and 13,213 women) aged 65 to 79 years from 1988-1990. The Cox proportional hazards model was used to calculate hazard ratio (HR) and 95% confidence interval (CI) for pneumonia mortality (ICD10: J9-18, J69) adjusted for age, sex, and possible confounders. P for trend was calculated across the categories of walking time. After a median of 11.9 years’ follow-up, 1,203 participants died of pneumonia. In participants without a medical history of MI or stroke, the HR of pneumonia mortality in participants who had walked at baseline for ≥1 h/day was 0.73 (95% CI, 0.62-0.85; P for trend &lt;0.001), compared with those who had walked for 0.5 h/day. Participants with a medical history of MI who walked for ≥1 h/day also showed significantly decreased risk of pneumonia mortality (HR, 0.49; 95% CI, 0.27-0.92; P for trend = 0.01). No significant associations were found among participants with a medical history of stroke (HR, 0.82; 95% CI, 0.39-1.72), although P for trend was statistically significant (P for trend = 0.003). However, the HR of pneumonia mortality in participants who had walked at baseline for &lt;0.5 h/day was 1.46 (95% CI, 1.19-1.78) in participants without a medical history of MI or stroke, 1.06 (95% CI, 0.46-2.25) in participants with a medical history of MI, and 2.83 (95% CI, 1.35-5.95) in participants with a medical history of stroke. Our findings suggest that longer walking time may be beneficial in reducing the risk of pneumonia mortality in elderly populations.
CROSS COUNTRY COMPARISON OF LEISURE TIME PHYSICAL ACTIVITY TRAJECTORIES IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERY DISEASE: INSIGHTS FROM THE PORTRAIT REGISTRY
Authors: Poghni Peri-Okonny, Ali Malik, Jeremy Provance, Vittal Hijjaji, Kensey Gosch, John A. Spertus, Kim Smolderen
Journal: Journal of the American College of Cardiology (2019)
Abstract 404: Sphingosine-1-phosphate Receptor 1 Inhibits Pathological Cardiac Remodeling Through Histone Deacetylases
Authors: Bisheng Zhou, Jayne Wolfe, Bianca Lavelle, Rishi Arora, J. Andrew Wasserstrom, Jerold Chun, Lisa D Wilsbacher
Journal: Circulation Research (2018)

Sphingosine-1-phosphate receptor 1 (S1P 1 , encoded by S1pr1 ) is a G protein-coupled receptor that signals in multiple cell types including endothelium and cardiomyocytes. We observed decreased cardiac S1PR1 mRNA in humans with nonischemic cardiomyopathy; these patterns were also observed in mice after cardiac stress. To assess the importance of reduced S1pr1 expression, we exposed S1pr1 heterozygous mice to isoproterenol or angiotensin II. Subsequently, hearts from S1pr1+/- mice displayed significantly higher markers of hypertrophy, inflammation, fibrosis, and oxidative stress than wild-type littermates. Cardiomyocyte-specific deletion of S1pr1 caused pronounced increases in the same markers. In wild-type mice, co-administration of the S1P 1 -specific agonist SEW2871 rescued the pathologic effects of angiotensin II. Because class I histone deacetylases (HDACs) contribute to pathological remodeling, we investigated interactions between S1P 1 and HDAC activities as a potential mechanism. In cultured mouse cardiomyocytes, angiotensin II increased expression of histone deacetylases 1 and 2, as well as other markers of pathological remodeling; co-treatment with SEW2871 inhibited these responses. Moreover, HDAC inhibition in S1pr1+/- mice blunted the pathological response to angiotensin II. These results indicate that S1P 1 protects by modulating HDAC1/2 during cardiac stress and support S1P 1 agonism as a therapeutic strategy for pathological cardiac remodeling in humans.
Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial
Authors: Kenneth G. Saag, Nicola Pannacciulli, Piet Geusens, Jonathan D. Adachi, Osvaldo D. Messina, Jorge Morales‐Torres, Ronald Emkey, Peter W. Butler, Xiang Yin, Willem F. Lems
Journal: Arthritis & Rheumatology (2019)

Objective Clinical trial results have shown that, in glucocorticoid‐treated patients, treatment with denosumab 60 mg subcutaneously once every 6 months (Q6M) increased spine and hip bone mineral density ( BMD ) at month 12 significantly more than treatment with risedronate 5 mg orally once daily ( QD ). The present analysis was performed to compare efficacy and characterize safety through month 24. Methods This phase III study enrolled men and women ≥18 years old who had received ≥7.5 mg daily prednisone or equivalent for &lt;3 months (glucocorticoid‐initiating) or for ≥3 months (glucocorticoid‐continuing) before screening. All patients &lt;50 years old had a history of osteoporotic fracture. Glucocorticoid‐continuing patients ≥50 years old had T scores of −2.0 or less (or −1.0 or less with fracture history). Patients were randomized (1:1) to receive denosumab 60 mg subcutaneously Q6M or risedronate 5 mg orally QD for 24 months, with daily calcium and vitamin D. Results Of 795 patients, 590 (74.2%) completed the study (in the glucocorticoid‐initiating group, 109 of 145 patients treated with denosumab and 117 of 145 patients treated with risedronate; in the glucocorticoid‐continuing group, 186 of 253 patients treated with denosumab and 178 of 252 patients treated with risedronate). Denosumab was superior to risedronate in increasing lumbar spine and total hip BMD at all time points assessed, among glucocorticoid‐initiating patients (24‐month lumbar spine: BMD increase of 6.2% versus 1.7%, respectively [ P &lt; 0.001]; 24‐month total hip: BMD increase of 3.1% versus 0.0% [ P &lt; 0.001]) and among glucocorticoid‐continuing patients (24‐month lumbar spine: BMD increase of 6.4% versus 3.2% [ P &lt; 0.001]; 24‐month total hip: BMD increase of 2.9% versus 0.5% [ P &lt; 0.001]). Adverse events, serious adverse events (including infections), and fractures were similar between treatment groups. Conclusion Denosumab was superior to risedronate in terms of increases in spine and hip BMD through month 24, and the safety profile was similar between treatment groups. Denosumab may offer a new osteoporosis treatment option for glucocorticoid‐treated patients.
THE EFFECTIVENESS AND SAFETY OF BALLOON PULMONARY ANGIOPLASTY FOR OLDEST OLD PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Authors: Nobutaka Ikeda, Shuji Kubota, Toru Okazaki, Raisuke Iijima, Hidehiko Hara, Yukio Hiroi, Masato Nakamura
Journal: Journal of the American College of Cardiology (2019)
ACCURACY OF HIGH-SENSITIVITY TROPONIN T: EFFECT OF SEX-SPECIFIC CUTOFFS AND IMPACT OF SERIAL CHANGE IN A UNITED STATES EMERGENCY CHEST PAIN POPULATION
Authors: Karanvir S. Grewal, Galen Hayek, Nathan Nahhas, Deep Shah, Shray Jain, Susan Fuhrman, Caroline Lerner, Anand Gupta, Tamara McMath
Journal: Journal of the American College of Cardiology (2019)
Abstract 299: Theranostic nanoparticles for Thrombosed Vessels: H <sub>2</sub> O <sub>2</sub> -Activatable Contrast-Enhanced Photoacoustic Imaging and Antithrombotic Therapy
Authors: Dongwon Lee
Journal: Circulation Research (2018)

A thrombus (blood clot) is formed in the injured vessels to maintain the integrity of vasculature. A thrombus, composed mainly of activated platelets and fibrin, obstructs arteries or veins, leading to various life-threatening diseases. During thrombus formation, H 2 O 2 (hydrogen peroxide) is overproduced by activated platelets and other vascular sources and serves as a key mediator of platelet activation and aggregation, facilitating inflammation and development of obstructive vascular diseases. In this regard, high level of H 2 O 2 holds great potential as diagnostic and therapeutic markers of obstructive capsular diseases. Inspired by the distinctive physicochemical characteristics of thrombi such as abundant fibrin and the significant of elevated level of H 2 O 2 , we developed H 2 O 2 -activatable novel nanomedicine (T-FBM) that could detect thrombi through the amplification of ultrasound/photoacoustic signal and serve as an antithrombotic nanomedicine. T-FBM nanoparticles were designed to target fibrin-rich thrombi and be activated by H 2 O 2 to generate CO 2 bubbles to amplify the photoacoustic signal. In the phantom studies, T-FBM nanoparticles showed significant amplification of ultrasound/photoacoustic signals in a H 2 O 2 -triggered manner. T-FBM nanoparticles also exerted H 2 O 2 -activatable antioxidant, anti-inflammatory and antiplatelet activities on endothelial cells. In mouse models of carotid arterial injury, T-FBM nanoparticles significantly enhanced the photoacoustic contrast specifically in thrombosed vessels and significantly suppressed thrombus formation. We anticipate that T-FBM nanoparticles hold great translational potential as nanotheranostics for H 2 O 2 -associated cardiovascular diseases.
AORTIC ROOT/ASCENDING AORTOPATHY IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS UNDERGOING CARDIAC MAGNETIC RESONANCE
Authors: Benjamin Sarac, Amgad Mentias, Pejman Raeisi-Giglou, Kevin Hodges, Zoran Popovic, Maran Thamilarasan, Harry Lever, Eric Roselli, Nicholas Smedira, Milind Desai
Journal: Journal of the American College of Cardiology (2019)
TERMINAL QRS DISTORTION IN STEMI AS A PREDICTION OF REPERFUSION FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Narut Prasitlumkun, Wasawat Vutthikraivit, Jakrin Kewcharoen, Nath Limpruttidham, Pattara Rattanawong
Journal: Journal of the American College of Cardiology (2019)
IMPACT OF MITRAL VALVE PATHOLOGY AND MITRACLIP CHARACTERISTICS ON RECURRENT MITRAL REGURGITATION AFTER TRANSCATHETER MITRAL VALVE REPAIR USING MITRACLIP
Authors: Syed Zaid, Hasan Ahmad, Joshua Goldberg, Tanya Dutta, Cenap Undemir, Ryan Kaple, Joanne Bennett, Martin Cohen, Steven Lansman, Gilbert Tang
Journal: Journal of the American College of Cardiology (2019)
POLYPHARMACY AND POTENTIALLY INAPPROPRIATE MEDICATION USE ARE UNIVERSAL AMONG PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
Authors: Lina Brinker, Jennifer L. McNamara, Matthew Konerman, Whitney E. Hornsby, Cristen J. Willer, Michael Brenner, Michael Dorsch, Scott Hummel, Parag Goyal
Journal: Journal of the American College of Cardiology (2019)
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology
Authors: Sebastian F Winter, Franziska Loebel, Jay Loeffler, Tracy T Batchelor, Maria Martinez-Lage, Peter Vajkoczy, Jorg Dietrich
Journal: Neuro-Oncology (2019)

Abstract Cancer therapy-induced adverse effects on the brain are a major challenge in neuro-oncology. Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity. A better understanding of the underlying mechanisms, improvement of diagnostic tools, development of preventive strategies, and implementation of evidence-based therapeutic practices are pivotal to improve patient management. In this comprehensive review, we address existing challenges associated with current TN-related clinical and research practices and highlight unanswered questions and areas in need of further research with the ultimate goal to improve management of patients affected by this important neuro-oncological condition.
IMPACT OF FISH OIL SUPPLEMENTATION ON ACUTE VASCULAR INFLAMMATION IN HEALTHY VOLUNTEERS
Authors: Anthony David Pisaniello, Peta King, Belinda A. Di Bartolo, Ge Liu, Robert A. Gibson, Joanne T.M. Tan, Christina A. Bursill, Peter Psaltis, Stephen Nicholls
Journal: Journal of the American College of Cardiology (2019)
MACHINE LEARNING PREDICTION MODELS FOR IN-HOSPITAL MORTALITY AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION AMONG RACIAL/ETHNIC MINORITY POPULATIONS IN THE UNITED STATES
Authors: Dagmar F. Hernandez-Suarez, Faraj Kargoli, Pedro Villablanca, Angel Lopez-Candales, Jose Wiley, Pedro Cox-Alomar, Brenda Nieves-Rodriguez, Roberto Feliu-Maldonado, Cristina Sanina, Jovaniel Rodriguez-Maldonado, Ricardo Nieves, Harish Ramakrishna, Abiel Roche-Lima
Journal: Journal of the American College of Cardiology (2019)
Natural history of multiple myeloma with de novo del(17p)
Authors: Arjun Lakshman, Utkarsh Painuly, S. Vincent Rajkumar, Rhett P. Ketterling, Prashant Kapoor, Patricia T. Greipp, Morie A. Gertz, Francis K. Buadi, Martha Q. Lacy, David Dingli, Angela Dispenzieri, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson I. Gonsalves, Yi Lisa Hwa, Nelson Leung, Ronald S. Go, Yi Lin, Taxiarchis V. Kourelis, Rahma Warsame, John A. Lust, Stephen J. Russell, Steven R. Zeldenrust, Robert A. Kyle, Shaji K. Kumar
Journal: Blood Cancer Journal (2019)

Abstract We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) ( n = 79) and standard-risk (SR) cytogenetics ( n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively ( P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, ( P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p ( n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.